Zimmer Biomet
ZBH
Market cap $18.1B

91.36 USD

-0.80

0.87%

Updated Jun 17, 10:44 AM EDT

1 day

-0.87%

5 days

-3.83%

1 month

-4.60%

3 months

-18.28%

6 months

-15.45%

Year to date

-12.54%

1 year

-14.64%

5 years

-28.66%

10 years

-18.79%

About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Employees: 17,000

Healthcare Medical Devices

0

Funds holding %

of 7,299 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

102% more call options, than puts

Call options by funds: $69.9M | Put options by funds: $34.6M

33% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 12 (+3) [Q1 2025]

7% more capital invested

Capital invested by funds: $19.2B [Q4 2024] → $20.6B (+$1.42B) [Q1 2025]

0.19% more ownership

Funds ownership: 91.4% [Q4 2024] → 91.59% (+0.19%) [Q1 2025]

3% less funds holding

Funds holding: 1,010 [Q4 2024] → 980 (-30) [Q1 2025]

12% less first-time investments, than exits

New positions opened: 86 | Existing positions closed: 98

25% less repeat investments, than reductions

Existing positions increased: 289 | Existing positions reduced: 385

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$95

4%

upside

Avg. target

$107

18%

upside

High target

$125

37%

upside

10 analyst ratings

6 positive

60%

4 neutral

40%

0 negative

0%

Canaccord Genuity William Plovanic	11%upside $101	Hold Maintained	12 May 2025
JMP Securities David Turkaly	37%upside $125	Market Outperform Maintained	7 May 2025
Goldman Sachs David Roman	14%upside $104	Neutral Maintained	6 May 2025
Raymond James Jayson Bedford	14%upside $104	Outperform Maintained	6 May 2025
Stifel Rick Wise	26%upside $115	Buy Maintained	6 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about ZBH published over the past 30 days

Zacks Investment Research

Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

WARSAW, Ind. , May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025.

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025

Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

WARSAW, Ind. , May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas.

Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m.

Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

CNBC Television

We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos

Ivan Tornos, Zimmer Biomet CEO, joins 'Closing Bell Overtime' from the CNBC CEO Council Summit to talk navigating a changing political landscape, partnering with Arnold Schwarzenegger and more.

We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos

24/7 Wall Street

Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys

If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.

Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys

Zacks Investment Research

ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues

These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday.

These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results

Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds

Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and competition. Zimmer Biomet's cash flows appear set to be particularly hard hit by tariffs, meaning the company's share price is likely to remain depressed until this is resolved.

Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

Zimmer Biomet Holdings, Inc ZBH reported first-quarter adjusted EPS of $1.81, down from $1.94 a year ago, beating the Street estimates of $1.77.

Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal

See News Rankings

Charts implemented using Lightweight Charts™